Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2010-09-27 Proxy Solicitation & In…
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2010-09-27 English
COPYTELE, INC. 10-Q
Interim / Quarterly Report 9M 2010
2010-09-14 English
COPYTELE, INC. 10-Q/A
Interim / Quarterly Report Q2 2010
2010-09-14 English
PRIMARY DOCUMENT
Director's Dealing
2010-08-24 English
COPYTELE, INC. 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new director to the company's Board of Directors, including information about the director's independence and related governance details. This fits the description of 'Board/Management Information' which covers announcements of changes in the company's board of directors or senior management. The document is not a full annual report, earnings release, or other financial report, but rather a governance-related announcement. The document length is 3472 characters, which is consistent with a typical 8-K filing for management changes. Therefore, the appropriate classification is MANG (Board/Management Information).
2010-08-20 English
Regulatory Filings 2010
Regulatory Filings Classification · 90% confidence The document text appears to be encoded or corrupted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. The length is 9258 characters, which is substantial, but the content is not interpretable as a financial report or announcement. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which is the default category for filings that do not fit other specific categories.
2010-07-27 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.